{"success":true,"data":{"pressRelease":{"id":"30693","rtpr_id":"nACSfj1BDa","ticker":"ADMA","exchange":"NASDAQ","all_tickers":["ADMA"],"title":"ROSEN, LEADING INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA","author":"ACCESSWIRE","published_at":"2026-05-12T00:00:00.708Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May\n11, 2026 / WHY: Rosen Law Firm, a global investor rights law firm, announces\nan investigation of potential securities claims on behalf of shareholders of\nADMA Biologics, Inc. (NASDAQ:ADMA) resulting from allegations that ADMA\nBiologics may have issued materially misleading business information to the\ninvesting public.\n\nSO WHAT: If you purchased ADMA Biologics securities you may be entitled to\ncompensation without payment of any out of pocket fees or costs through a\ncontingency fee arrangement. The Rosen Law Firm is preparing a class action\nseeking recovery of investor losses.\n\nWHAT TO DO NEXT: To join the prospective class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=57940 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action.\n\nWHAT IS THIS ABOUT: On March 24, 2026, Investing.com published an article\nentitled \"ADMA Biologics shares plunge on short seller allegations.\" The\narticle stated that ADMA Biologics shares fell \"after short seller Culper\nResearch released a report alleging the company engaged in channel stuffing to\ninflate revenue growth.\"\n\nOn this news, ADMA Biologics stock fell 16.6% on March 24, 2026.\n\nWHY ROSEN LAW: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer recognition.\nMany of these firms do not actually litigate securities class actions. Be wise\nin selecting counsel. The Rosen Law Firm represents investors throughout the\nglobe, concentrating its practice in securities class actions and shareholder\nderivative litigation. Rosen Law Firm has achieved, at that time, the largest\never securities class action settlement against a Chinese Company. At the time\nRosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for\nnumber of securities class action settlements in 2017. The firm has been\nranked in the top 4 each year since 2013 and has recovered hundreds of\nmillions of dollars for investors. In 2019 alone the firm secured over $438\nmillion for investors. In 2020, founding partner Laurence Rosen was named by\nlaw360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been\nrecognized by Lawdragon and Super Lawyers.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm, on Twitter:\nhttps://twitter.com/rosen_firm or on Facebook:\nhttps://www.facebook.com/rosenlawfirm/.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\n-------------------------------\n\nContact Information:\n\nLaurence Rosen, Esq.\nPhillip Kim, Esq.\nThe Rosen Law Firm, P.A.\n275 Madison Avenue, 40th Floor\nNew York, NY 10016\nTel: (212) 686-1060\nToll Free: (866) 767-3653\nFax: (212) 202-3827\ncase@rosenlegal.com\nwww.rosenlegal.com\n\nSOURCE: The Rosen Law Firm, P.A.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/rosen-leading-investor-counsel-encourages-adma-biologics-inc.-in-1165791)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSfj1BDa","title":"ROSEN, LEADING INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA","author":"ACCESSWIRE","ticker":"ADMA","created":"2026-05-12T00:00:00.708Z","tickers":["ADMA"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May\n11, 2026 / WHY: Rosen Law Firm, a global investor rights law firm, announces\nan investigation of potential securities claims on behalf of shareholders of\nADMA Biologics, Inc. (NASDAQ:ADMA) resulting from allegations that ADMA\nBiologics may have issued materially misleading business information to the\ninvesting public.\n\nSO WHAT: If you purchased ADMA Biologics securities you may be entitled to\ncompensation without payment of any out of pocket fees or costs through a\ncontingency fee arrangement. The Rosen Law Firm is preparing a class action\nseeking recovery of investor losses.\n\nWHAT TO DO NEXT: To join the prospective class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=57940 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action.\n\nWHAT IS THIS ABOUT: On March 24, 2026, Investing.com published an article\nentitled \"ADMA Biologics shares plunge on short seller allegations.\" The\narticle stated that ADMA Biologics shares fell \"after short seller Culper\nResearch released a report alleging the company engaged in channel stuffing to\ninflate revenue growth.\"\n\nOn this news, ADMA Biologics stock fell 16.6% on March 24, 2026.\n\nWHY ROSEN LAW: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer recognition.\nMany of these firms do not actually litigate securities class actions. Be wise\nin selecting counsel. The Rosen Law Firm represents investors throughout the\nglobe, concentrating its practice in securities class actions and shareholder\nderivative litigation. Rosen Law Firm has achieved, at that time, the largest\never securities class action settlement against a Chinese Company. At the time\nRosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for\nnumber of securities class action settlements in 2017. The firm has been\nranked in the top 4 each year since 2013 and has recovered hundreds of\nmillions of dollars for investors. In 2019 alone the firm secured over $438\nmillion for investors. In 2020, founding partner Laurence Rosen was named by\nlaw360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been\nrecognized by Lawdragon and Super Lawyers.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm, on Twitter:\nhttps://twitter.com/rosen_firm or on Facebook:\nhttps://www.facebook.com/rosenlawfirm/.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\n-------------------------------\n\nContact Information:\n\nLaurence Rosen, Esq.\nPhillip Kim, Esq.\nThe Rosen Law Firm, P.A.\n275 Madison Avenue, 40th Floor\nNew York, NY 10016\nTel: (212) 686-1060\nToll Free: (866) 767-3653\nFax: (212) 202-3827\ncase@rosenlegal.com\nwww.rosenlegal.com\n\nSOURCE: The Rosen Law Firm, P.A.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/rosen-leading-investor-counsel-encourages-adma-biologics-inc.-in-1165791)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-12T00:00:00.75267729Z","server_sent_at_ms":1778544000752},"received_at":"2026-05-12T00:00:00.814Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/rosen-leading-investor-counsel-encourages-adma-biologics-inc.-in-1165791"},"analysis":null,"durationMs":null,"modelName":null}}